All In Biotech

Drug Trial Radar · NCT02531516

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,503 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,503

Actual

Start

Nov 19, 2015

Primary completion

Mar 1, 2027

Study completion Dec 29, 2028

Sponsor

Lead sponsor
Aragon Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival (MFS) based on conventional imaging assessed by blinded independent central review (BICR).

Conditions

  • Prostatic Neoplasms

Interventions

  • ApalutamideDrug

  • BicalutamideDrug

  • Bicalutamide PlaceboDrug

  • Apalutamide PlaceboDrug

  • GnRH (agonist)Drug

  • 74-80 Grays (units of radiation)Radiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Metastasis-Free Survival (MFS)Time frame: 108 Months

Locations

263 sites in 23 countries. Site status is shown where the registry gives one.

  • Site not named

    Homewood, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Bakersfield, California

  • Site not named

    Los Angeles, California

  • Site not named

    Orange, California

  • Site not named

    San Bernardino, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Middlebury, Connecticut

  • Site not named

    Bradenton, Florida

  • Site not named

    Daytona Beach, Florida

  • Site not named

    Fort Myers, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Lakewood Rch, Florida

  • Site not named

    Naples, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Meridian, Idaho

  • Site not named

    Evergreen Park, Illinois

  • Site not named

    Harvey, Illinois

  • Site not named

    Jeffersonville, Indiana

  • Site not named

    Wichita, Kansas

  • Site not named

    Ashland, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Scarborough, Maine

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    St Louis, Missouri

  • Site not named

    Morristown, New Jersey

  • Site not named

    Albany, New York

  • Site not named

    Brooklyn, New York

  • Site not named

    New York, New York

  • Site not named

    Poughkeepsie, New York

  • Site not named

    Rochester, New York

  • Site not named

    Syracuse, New York

  • Site not named

    The Bronx, New York

Showing 40 of 263 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.